A CCEPTED MANUSCRIPT
References
1. Zhou, Y., Boudreau, D. M. & Freedman, A. N. Trends in the use of aspirin and nonsteroidal
anti-inflammatory drugs in the general U.S. population. Pharmacoepidemiol. Drug Saf. 23,
43–50 (2014).
2. Stuntz, M. & Bernstein, B. Recent trends in the prevalence of low-dose aspirin use for
primary and secondary prevention of cardiovascular disease in the United States, 2012–2015.
Prev. Med. Reports 5, 183–186 (2017).
3. Goldstein, J. L. & Cryer, B. Gastrointestinal injury associated with NSAID use: a case study
and review of risk factors and preventative strategies. Drug. Healthc. Patient Saf. 7, 31–41
(2015).
4. Sostres, C. & Gargallo, C. J. Gastrointestinal lesions and complications of low-dose aspirin
in the gastrointestinal tract. Best Pract. Res. Clin. Gastroenterol. 26, 141–151 (2012).
MANUSCRIPT
5. McNeil, J. J. et al. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy
Elderly. N. Engl. J. Med. 379, 1509–1518 (2018).
6. Zheng, S. L. & Roddick, A. J. Association of Aspirin Use for Primary Prevention With
Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis. JAMA
321, 277–287 (2019).
7. Bjarnason, I. et al. Mechanisms of Damage to the Gastrointestinal Tract From Nonsteroidal
Anti-Inflammatory Drugs. Gastroenterology 154, 500–514 (2018).
8. Wallace, J. L. NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates
distinct prevention strategies. Br. J. Pharmacol. 165, 67–74 (2012).
9. Washio, E. et al. Proton Pump Inhibitors Increase Incidence of Nonsteroidal Anti-
Inflammatory Drug–Induced Small Bowel Injury: A Randomized, Placebo-Controlled Trial.
Clin. Gastroenterol. Hepatol. 14, 809–815.e1 (2016).
19
Powered by FlippingBook